MA51339A - Procédé de préparation de composés pyrimidinyl-4-aminopyrazole - Google Patents

Procédé de préparation de composés pyrimidinyl-4-aminopyrazole

Info

Publication number
MA51339A
MA51339A MA051339A MA51339A MA51339A MA 51339 A MA51339 A MA 51339A MA 051339 A MA051339 A MA 051339A MA 51339 A MA51339 A MA 51339A MA 51339 A MA51339 A MA 51339A
Authority
MA
Morocco
Prior art keywords
pyrimidinyl
preparation
aminopyrazole compounds
aminopyrazole
compounds
Prior art date
Application number
MA051339A
Other languages
English (en)
Inventor
Travis Remarchuk
Anantha Sudhakar
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MA51339A publication Critical patent/MA51339A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051339A 2017-12-20 2018-12-19 Procédé de préparation de composés pyrimidinyl-4-aminopyrazole MA51339A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762608398P 2017-12-20 2017-12-20

Publications (1)

Publication Number Publication Date
MA51339A true MA51339A (fr) 2020-10-28

Family

ID=66994244

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051339A MA51339A (fr) 2017-12-20 2018-12-19 Procédé de préparation de composés pyrimidinyl-4-aminopyrazole

Country Status (14)

Country Link
US (2) US11834438B2 (fr)
EP (1) EP3727377B1 (fr)
JP (1) JP7284172B2 (fr)
KR (1) KR20200100757A (fr)
CN (1) CN112088003B (fr)
AU (1) AU2018392599A1 (fr)
BR (1) BR112020012611A2 (fr)
CA (1) CA3086182A1 (fr)
ES (1) ES2975958T3 (fr)
IL (1) IL275480B2 (fr)
MA (1) MA51339A (fr)
MX (1) MX2020006641A (fr)
SG (1) SG11202005752PA (fr)
WO (1) WO2019126383A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086182A1 (fr) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Procede de preparation de composes pyrimidinyl-4-aminopyrazole
AR118641A1 (es) * 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos
CN115894456A (zh) * 2022-11-13 2023-04-04 药康众拓(江苏)医药科技有限公司 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
SI2638031T1 (en) 2010-11-10 2018-02-28 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
CA2852609C (fr) 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag Derives aminopyridines en tant que modulateurs de lrrk2
LT2785711T (lt) 2011-11-29 2016-10-25 F.Hoffmann-La Roche Ag 2-(fenil arba pirid-3-il)aminopirimidino dariniai kaip kinazės lrrk2 moduliatoriai skirti parkinsono ligos gydymui
CN103958498B (zh) 2011-11-29 2016-09-07 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
BR112014012822A8 (pt) 2011-11-30 2017-07-11 Hoffmann La Roche Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
WO2013164321A1 (fr) 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Dérivés de pyrazole aminopyrimidine en tant que modulateurs de lrrk2
BR112014027117B1 (pt) 2012-05-03 2022-09-06 Genentech, Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
CN104736533B (zh) * 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
WO2017019804A2 (fr) 2015-07-28 2017-02-02 Plexxikon Inc. Composés et procédés de modulation des kinases, et indications associées
WO2017087905A1 (fr) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Composés, compositions, et procédés
US11028080B2 (en) * 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
IL299415B2 (en) 2016-06-16 2025-09-01 Denali Therapeutics Inc Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
US20200157081A1 (en) 2017-05-24 2020-05-21 Denali Therapeutics Inc. Compounds, compositions and methods
AR113893A1 (es) 2017-11-21 2020-06-24 Denali Therapeutics Inc Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
CA3086182A1 (fr) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Procede de preparation de composes pyrimidinyl-4-aminopyrazole
AR118641A1 (es) 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos

Also Published As

Publication number Publication date
WO2019126383A1 (fr) 2019-06-27
BR112020012611A2 (pt) 2020-12-08
US20210009566A1 (en) 2021-01-14
IL275480A (en) 2020-08-31
IL275480B2 (en) 2023-10-01
MX2020006641A (es) 2021-01-08
CN112088003A (zh) 2020-12-15
KR20200100757A (ko) 2020-08-26
US20240158371A1 (en) 2024-05-16
EP3727377A1 (fr) 2020-10-28
CA3086182A1 (fr) 2019-06-27
ES2975958T3 (es) 2024-07-18
AU2018392599A1 (en) 2020-07-09
US11834438B2 (en) 2023-12-05
SG11202005752PA (en) 2020-07-29
JP7284172B2 (ja) 2023-05-30
US12497387B2 (en) 2025-12-16
EP3727377B1 (fr) 2024-01-31
IL275480B1 (en) 2023-06-01
EP3727377A4 (fr) 2021-08-18
JP2021506892A (ja) 2021-02-22
CN112088003B (zh) 2023-10-13

Similar Documents

Publication Publication Date Title
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
EP3398960A4 (fr) Procédé de préparation du sermaglutide
MA54253A (fr) Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines
EP3349586A4 (fr) Procédé de préparation d'un composé antifongique
EP3500551A4 (fr) Procédé de préparation de biphényles substitués
MA42423A (fr) Procédé de préparation d'un revêtement
EP3766869A4 (fr) Procédé simple de préparation d'avibactam
EP3400197A4 (fr) Procédé améliore de préparation de bleu isosulfane
EP3436425A4 (fr) Procédé de préparation amélioré de tartrate de butorphanol
EP3696168A4 (fr) Procédé de préparation de 2-chloro-5-trifluorométhylpyridine
EP3539941A4 (fr) Procédé de préparation triméthylolpropane
EP3511313A4 (fr) Procédé de préparation de 1,3-cyclohexanediméthanol
MA51870A (fr) Procédé pour la préparation de composés coupleurs de médicaments
EP3350154A4 (fr) Procédé amélioré de préparation de dichlorhydrate de trientine
EP3505525A4 (fr) Procédé de préparation de rubusoside
EP3727377A4 (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
EP3770239A4 (fr) Procédé de préparation de microcapsules
EP3981753A4 (fr) Procédé de préparation de triphénylchlorométhane
EP3444253A4 (fr) Procédé de préparation de ad-35
EP3666756A4 (fr) Procédé de préparation de lévétiracétam
EP3455210A4 (fr) Procédé de préparation de boscalide
EP3733651A4 (fr) Procédé de préparation de calcobutrol
EP3359512A4 (fr) Procédé de préparation de bromures organiques
EP3786152A4 (fr) Procédé de préparation de composé nitrile aromatique
EP3395786A4 (fr) Procédé de préparation de butadiène